AstraZeneca announced "positive" high-level results from the ADAURA Phase III trial showed AstraZeneca’s Tagrisso demonstrated a statistically significant and clinically meaningful improvement in overall survival, or OS, a key secondary endpoint, compared to placebo in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer, or NSCLC, after complete tumor resection with curative intent. In May 2020, AstraZeneca announced Tagrisso demonstrated a statistically significant and clinically meaningful improvement in disease-free survival, or DFS, in this setting. In September 2022, updated results demonstrated a median DFS of nearly five and a half years. Per the ADAURA trial protocol, patients on placebo that recurred with metastatic disease had the opportunity to receive open-label Tagrisso, the company said.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AZN:
- Guggenheim starts Mineralys at Buy, sees multibillion-dollar potential for ASIs
- Mineralys Therapeutics initiated with an Outperform at Evercore ISI
- AstraZeneca, Daiichi Sankyo announce Enhertu met the prespecified target for ORR
- AstraZeneca says Enhertu met prespecified criteria for ORR in DESTINY-PanTumor02
- AstraZeneca says FDA to convene AdCom meeting on sNDA for Lynparza in mCRPC